Deal History

Joint book-running manager for Veradermics IPO (February 2026). Dermatology-focused biotechnology company. Recent capital markets transaction demonstrating continued equity issuance strength.

Joint book-running manager for Evommune IPO (November 2025). Immunology-focused biotechnology company. Demonstrates strength in healthcare capital markets and equity issuance advisory.

Co-financial advisor (with Centerview Partners) on sale of gene therapy company to strategic acquirer. Decibel Therapeutics, a clinical-stage biotech focused on gene therapy for hearing loss (DB-OTO program), sold to Regeneron. Deal included $109M upfront payment plus up to $3.50/share in contingent value rights based on clinical and regulatory milestones. Valued company at $109M-$213M depending on milestone achievement.

Exclusive financial advisory on Freeline Therapeutics acquisition. Gene therapy company focused on rare disease. Transaction demonstrates experience with clinical-stage biotech M&A.

Exclusive financial advisor to Graphite Bio on proposed merger with LENZ Therapeutic. Gene therapy focused biotechnology transaction demonstrating expertise in advanced therapeutics M&A.

Exclusive financial advisor to Q32 Bio on M&A transaction. Biotechnology company transaction demonstrates active practice in biopharma advisory.

Exclusive financial advisory on Neoleukin Therapeutics acquisition. Biotechnology company focused on immunology. Transaction demonstrates firm's engagement across diverse therapeutic areas.

Exclusive financial advisor to Community Health Systems on sale of four Northwest Arkansas hospital operations. Transaction value of $112M with expected closing Q2 2026. Demonstrates firm's expertise in healthcare services divestitures and hospital system transactions.